Effects of ebselen addition on emotional processing and brain neurochemistry in depressed patients unresponsive to antidepressant medication

Lithium is an effective augmenting agent for depressed patients with inadequate response to standard antidepressant therapy, but numerous adverse effects limit its use. We previously reported that a lithium-mimetic agent, ebselen, promoted a positive emotional bias—an indicator of potential antidepr...

Full description

Bibliographic Details
Main Authors: Ramli, FF, Singh, N, Emir, UE, Villa, LM, Waters, S, Harmer, CJ, Cowen, PJ, Godlewska, BR
Format: Journal article
Language:English
Published: Springer Nature [academic journals on nature.com] 2024
_version_ 1811140089779060736
author Ramli, FF
Singh, N
Emir, UE
Villa, LM
Waters, S
Harmer, CJ
Cowen, PJ
Godlewska, BR
author_facet Ramli, FF
Singh, N
Emir, UE
Villa, LM
Waters, S
Harmer, CJ
Cowen, PJ
Godlewska, BR
author_sort Ramli, FF
collection OXFORD
description Lithium is an effective augmenting agent for depressed patients with inadequate response to standard antidepressant therapy, but numerous adverse effects limit its use. We previously reported that a lithium-mimetic agent, ebselen, promoted a positive emotional bias—an indicator of potential antidepressant activity in healthy participants. We therefore aimed to investigate the effects of short-term ebselen treatment on emotional processing and brain neurochemistry in depressed patients with inadequate response to standard antidepressants. We conducted a double-blind, placebo-controlled 7-day experimental medicine study in 51 patients with major depressive disorder who were currently taking antidepressants but had an inadequate response to treatment. Participants received either ebselen 600 mg twice daily for seven days or identical matching placebo. An emotional testing battery, magnetic resonance spectroscopy and depression and anxiety rating scales were conducted at baseline and after seven days of treatment. Ebselen did not increase the recognition of positive facial expressions in the depressed patient group. However, ebselen increased the response bias towards fear emotion in the signal detection measurement. In the anterior cingulate cortex, ebselen significantly reduced the concentrations of inositol and Glx (glutamate+glutamine). We found no significant differences in depression and anxiety rating scales between visits. Our study did not find any positive shift in emotional bias in depressed patients with an inadequate response to antidepressant medication. We confirmed the ability of ebselen to lower inositol and Glx in the anterior cingulate cortex. These latter effects are probably mediated through inhibition of inositol monophosphatase and glutaminase respectively.
first_indexed 2024-09-25T04:16:27Z
format Journal article
id oxford-uuid:07b54fe8-bd16-4568-a45e-f88c4cf7022d
institution University of Oxford
language English
last_indexed 2024-09-25T04:16:27Z
publishDate 2024
publisher Springer Nature [academic journals on nature.com]
record_format dspace
spelling oxford-uuid:07b54fe8-bd16-4568-a45e-f88c4cf7022d2024-07-20T15:35:27ZEffects of ebselen addition on emotional processing and brain neurochemistry in depressed patients unresponsive to antidepressant medicationJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:07b54fe8-bd16-4568-a45e-f88c4cf7022dEnglishJisc Publications RouterSpringer Nature [academic journals on nature.com]2024Ramli, FFSingh, NEmir, UEVilla, LMWaters, SHarmer, CJCowen, PJGodlewska, BRLithium is an effective augmenting agent for depressed patients with inadequate response to standard antidepressant therapy, but numerous adverse effects limit its use. We previously reported that a lithium-mimetic agent, ebselen, promoted a positive emotional bias—an indicator of potential antidepressant activity in healthy participants. We therefore aimed to investigate the effects of short-term ebselen treatment on emotional processing and brain neurochemistry in depressed patients with inadequate response to standard antidepressants. We conducted a double-blind, placebo-controlled 7-day experimental medicine study in 51 patients with major depressive disorder who were currently taking antidepressants but had an inadequate response to treatment. Participants received either ebselen 600 mg twice daily for seven days or identical matching placebo. An emotional testing battery, magnetic resonance spectroscopy and depression and anxiety rating scales were conducted at baseline and after seven days of treatment. Ebselen did not increase the recognition of positive facial expressions in the depressed patient group. However, ebselen increased the response bias towards fear emotion in the signal detection measurement. In the anterior cingulate cortex, ebselen significantly reduced the concentrations of inositol and Glx (glutamate+glutamine). We found no significant differences in depression and anxiety rating scales between visits. Our study did not find any positive shift in emotional bias in depressed patients with an inadequate response to antidepressant medication. We confirmed the ability of ebselen to lower inositol and Glx in the anterior cingulate cortex. These latter effects are probably mediated through inhibition of inositol monophosphatase and glutaminase respectively.
spellingShingle Ramli, FF
Singh, N
Emir, UE
Villa, LM
Waters, S
Harmer, CJ
Cowen, PJ
Godlewska, BR
Effects of ebselen addition on emotional processing and brain neurochemistry in depressed patients unresponsive to antidepressant medication
title Effects of ebselen addition on emotional processing and brain neurochemistry in depressed patients unresponsive to antidepressant medication
title_full Effects of ebselen addition on emotional processing and brain neurochemistry in depressed patients unresponsive to antidepressant medication
title_fullStr Effects of ebselen addition on emotional processing and brain neurochemistry in depressed patients unresponsive to antidepressant medication
title_full_unstemmed Effects of ebselen addition on emotional processing and brain neurochemistry in depressed patients unresponsive to antidepressant medication
title_short Effects of ebselen addition on emotional processing and brain neurochemistry in depressed patients unresponsive to antidepressant medication
title_sort effects of ebselen addition on emotional processing and brain neurochemistry in depressed patients unresponsive to antidepressant medication
work_keys_str_mv AT ramliff effectsofebselenadditiononemotionalprocessingandbrainneurochemistryindepressedpatientsunresponsivetoantidepressantmedication
AT singhn effectsofebselenadditiononemotionalprocessingandbrainneurochemistryindepressedpatientsunresponsivetoantidepressantmedication
AT emirue effectsofebselenadditiononemotionalprocessingandbrainneurochemistryindepressedpatientsunresponsivetoantidepressantmedication
AT villalm effectsofebselenadditiononemotionalprocessingandbrainneurochemistryindepressedpatientsunresponsivetoantidepressantmedication
AT waterss effectsofebselenadditiononemotionalprocessingandbrainneurochemistryindepressedpatientsunresponsivetoantidepressantmedication
AT harmercj effectsofebselenadditiononemotionalprocessingandbrainneurochemistryindepressedpatientsunresponsivetoantidepressantmedication
AT cowenpj effectsofebselenadditiononemotionalprocessingandbrainneurochemistryindepressedpatientsunresponsivetoantidepressantmedication
AT godlewskabr effectsofebselenadditiononemotionalprocessingandbrainneurochemistryindepressedpatientsunresponsivetoantidepressantmedication